                                SEQUENCE LISTING

<110> Goldstein, Joshua
      Cohen, Steven B.
      Schumacher, Andrew
      Yowe, David

<120> PCSK9 Antagonists
  

<130> PAT054416-WO-PCT

<140> Not yet assigned 
<141> 2012-02-10  

<150> US 61/442,126
<151> 2011-02-11

<160> 55

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 119
<212> PRT
<213> Mus musculus

<220> 
<223> mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody MAB1
      heavy chain variable region (FR1 through FR4)

<400> 1
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1               5                  10                  15      
Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Glu Gly Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Val Ser Lys Asp Thr Ser Ser Asn Gln Val
65                  70                  75                  80  
Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Leu Ile Thr Thr Glu Gly Gly Phe Ala Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ala
        115                 


<210> 2
<211> 357
<212> DNA
<213> Mus musculus

<220> 
<223> mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody MAB1
      heavy chain variable region (FR1 through FR4)

<400> 2
caggttactc tgaaagagtc tggccctggg atattgcagc cctcccagac cctcagtctg 60
acttgttctt tctctgggtt ttcgctgagc acttctggta tgggtgtagg ctggattcgt 120
cagccttcag gagagggtct agagtggctg gcagacattt ggtgggatga caataagtac 180
tataacccat ccctgaagag ccggctcaca gtctccaagg atacctccag caaccaggtc 240
ttcctcaaga tcaccagtgt ggacactgca gatactgcca cttactactg tgcccttatt 300
actacggagg gggggtttgc ttactggggc caagggactc tggtcactgt ctctgca    357

<210> 3
<211> 107
<212> PRT
<213> Mus musculus

<220> 
<223> mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody MAB1
      light chain variable region (FR1 through FR4)

<400> 3
Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
 1               5                  10                  15      
Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Asn Asn Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Lys Phe Ala Ser Arg Ser Ile Ser Gly Ile Pro Ser Lys Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr
65                  70                  75                  80  
Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Tyr Trp Pro Leu
                85                  90                  95      
Thr Phe Gly Ala Gly Thr Asn Leu Glu Leu Ile
            100                 105         


<210> 4
<211> 321
<212> DNA
<213> Mus musculus

<220> 
<223> mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody MAB1
      light chain variable region (FR1 through FR4)

<400> 4
gatattgtgc taactcagtc tccagccacc ctgtctgtga ctcctggaga tagcgtcagt 60
ctttcctgca gggccagcca aagtattaac aacaacctac actggtatca acaaaaatca 120
catgagtctc caaggcttct catcaaattt gcttcccggt ccatctctgg gatcccctcc 180
aagttcagtg gcagtggatc agggacagat ttcactctca gtatcaacag tgtggagact 240
gaagattttg gaatgtattt ctgtcaacag agtaattact ggcctctcac gttcggtgct 300
gggaccaacc tggagctgat a                                           321

<210> 5
<211> 119
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB2 heavy chain variable region (FR1 through FR4)

<400> 5
Gln Ile Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg Ile Thr Thr Glu Gly Gly Phe Ala Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser
        115                 


<210> 6
<211> 357
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB2 heavy chain variable region (FR1 through FR4)

<400> 6
cagatcacct tgaaggagtc tggtcctgtg ctggtgaaac ccacagagac cctcacgctg 60
acctgcaccg tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 120
cagcccccag gaaaggccct ggagtggctt gcagacattt ggtgggatga caataagtac 180
tataacccat ccctgaagag ccggctcacc atctccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catactactg cgcacgtatt 300
actaccgaag gtggctttgc ctactggggc cagggtaccc ttgtgaccgt gagctcc    357

<210> 7
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB2 light chain variable region (FR1 through FR4)

<400> 7
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln Arg Ile Ser His Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Asn Phe Ala Ser Arg Leu Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Tyr Trp Pro Leu
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 8
<211> 321
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB2 light chain variable region (FR1 through FR4)

<400> 8
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtagggga cagagtcacc 60
atcacttgcc gggcaggtca gcgcattagc cacaatttac attggtatca gcagaaacca 120
gacgagtctc cgagattact tattaacttc gccagtagat tgataagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcagcag agcaactatt ggccgctgac ctttggccaa 300
ggtacgaagc ttgaaattaa a                                           321

<210> 9
<211> 119
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB3 heavy chain variable region (FR1 through FR4)

<400> 9
Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Val Gly Val Gly Trp Ile Arg Gln Ser Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg Ile Thr Thr Glu Gly Gly Phe Ala Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser
        115                 


<210> 10
<211> 357
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB3 heavy chain variable region (FR1 through FR4)

<400> 10
caggtcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcaccg tctctggatt ctcactcagc acaagtggag tgggtgtggg ctggatccgt 120
cagtccccag gaaaggccct ggagtggctt gcagacattt ggtgggatga caataagtac 180
tataacccat ccctgaagag ccggctcacc atctccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catactactg cgcacgtatt 300
actaccgaag gtggctttgc ctactggggc cagggtaccc ttgtgaccgt gagctcc    357

<210> 11
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB3 light chain variable region (FR1 through FR4)

<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln Arg Ile Ser His Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Asn Phe Ala Ser Arg Leu Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Tyr Trp Pro Leu
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 12
<211> 321
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB3 light chain variable region (FR1 through FR4)

<400> 12
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtagggga cagagtcacc 60
atcacttgcc gggcaggtca gcgcattagc cacaatttac attggtatca gcagaaacca 120
gacgagtctc cgagattact tattaacttc gccagtagat tgataagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcagcag agcaactatt ggccgctgac ctttggccaa 300
ggtacgaagc ttgaaattaa a                                           321

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibody MAB1 heavy chain CDR1

<400> 13
Thr Ser Gly Met Gly Val Gly
 1               5          


<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibodies MAB2 and MAB3 heavy chain CDR1

<400> 14
Thr Ser Gly Val Gly Val Gly
 1               5          


<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody heavy
      chain variable region CDR1 consensus sequence

<220> 
<221> VARIANT        
<222> (4)...(4)
<223> Xaa = Met or Val

<400> 15
Thr Ser Gly Xaa Gly Val Gly
 1               5          


<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibodies MAB1,
      MAB2 and MAB3 heavy chain variable region CDR2

<400> 16
Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser Leu Lys Ser
 1               5                  10                  15      


<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibodies MAB1,
      MAB2 and MAB3 heavy chain variable region CDR3

<400> 17
Ile Thr Thr Glu Gly Gly Phe Ala Tyr
 1               5                  


<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibody MAB1 light chain variable region CDR1

<400> 18
Arg Ala Ser Gln Ser Ile Asn Asn Asn Leu His
 1               5                  10      


<210> 19
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region CDR1

<400> 19
Arg Ala Gly Gln Arg Ile Ser His Asn Leu His
 1               5                  10      


<210> 20
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody light
      chain variable region CDR1 consensus sequence

<220> 
<221> VARIANT        
<222> (3)...(3)
<223> Xaa = Gly or Ser

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Arg or Ser

<220> 
<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Asn or Ser

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = His or Asn

<400> 20
Arg Ala Xaa Gln Xaa Ile Xaa Xaa Asn Leu His
 1               5                  10      


<210> 21
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibody MAB1 light chain variable region CDR2

<400> 21
Phe Ala Ser Arg Ser Ile Ser
 1               5          


<210> 22
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region CDR2

<400> 22
Phe Ala Ser Arg Leu Ile Ser
 1               5          


<210> 23
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody light
      chain variable region CDR2 consensus sequence

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Leu or Ser

<400> 23
Phe Ala Ser Arg Xaa Ile Ser
 1               5          


<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibodies MAB1,
      MAB2 and MAB3 light chain variable region CDR3

<400> 24
Gln Gln Ser Asn Tyr Trp Pro Leu Thr
 1               5                  


<210> 25
<211> 99
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB2 heavy chain variable segment (FR1 through FR3)

<400> 25
Gln Ile Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg
            

<210> 26
<211> 99
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibody
      MAB3 heavy chain variable segment (FR1 through FR3)

<400> 26
Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Val Gly Val Gly Trp Ile Arg Gln Ser Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg
            

<210> 27
<211> 99
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody heavy chain
      variable segment (FR1 through FR3) consensus sequence

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Ile or Val

<220> 
<221> VARIANT        
<222> (34)...(34)
<223> Xaa = Met or Val

<400> 27
Gln Xaa Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glx
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Xaa Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg
            

<210> 28
<211> 88
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibodies MAB2 and MAB3
      light chain variable segment (FR1 through FR3)

<400> 28
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln Arg Ile Ser His Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Asn Phe Ala Ser Arg Leu Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys
                85              


<210> 29
<211> 88
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody light chain
      variable segment (FR1 through FR3) consensus sequence

<220> 
<221> VARIANT        
<222> (26)...(26)
<223> Xaa = Gly or Ser

<220> 
<221> VARIANT        
<222> (28)...(28)
<223> Xaa = Arg or Ser

<220> 
<221> VARIANT        
<222> (30)...(30)
<223> Xa = Asn or Ser

<220> 
<221> VARIANT        
<222> (31)...(31)
<223> Xaa = His or Asn

<400> 29
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Xaa Gln Xaa Ile Xaa Xaa Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Asn Phe Ala Ser Arg Leu Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys
                85              


<210> 30
<211> 30
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibody MAB2 heavy chain variable region FR1

<400> 30
Gln Ile Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser
            20                  25                  30  


<210> 31
<211> 30
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9)
      antibody MAB3 heavy chain variable region FR1

<400> 31
Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Gln
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser
            20                  25                  30  


<210> 32
<211> 30
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibodies MAB2 and MAB3
      heavy chain variable region FR1 consensus sequence

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Ile or Val

<400> 32
Gln Xaa Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glx
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser
            20                  25                  30  


<210> 33
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 heavy chain variable region FR2

<400> 33
Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala
 1               5                  10                  


<210> 34
<211> 32
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 heavy chain variable region FR3

<400> 34
Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr
 1               5                  10                  15      
Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
            20                  25                  30          


<210> 35
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 heavy chain variable region FR4

<400> 35
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1               5                  10      


<210> 36
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region FR1

<400> 36
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys
            20              


<210> 37
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region FR2

<400> 37
Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile Asn
 1               5                  10                  15  


<210> 38
<211> 32
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region FR3

<400> 38
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 1               5                  10                  15      
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
            20                  25                  30          


<210> 39
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PSCK9) antibodies
      MAB2 and MAB3 light chain variable region FR4

<400> 39
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 1               5                  10  


<210> 40
<211> 119
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody heavy chain
      variable region (FR1 through FR4) consensus sequence

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Ile or Val

<220> 
<221> VARIANT        
<222> (34)...(34)
<223> Xaa = Met or Val

<400> 40
Gln Xaa Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glx
 1               5                  10                  15      
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Ser
            20                  25                  30          
Gly Xaa Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
        35                  40                  45              
Trp Leu Ala Asp Ile Trp Trp Asp Asp Asn Lys Tyr Tyr Asn Pro Ser
    50                  55                  60                  
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65                  70                  75                  80  
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95      
Cys Ala Arg Ile Thr Thr Glu Gly Gly Phe Ala Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser
        115                 


<210> 41
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) antibody light chain
      variable region (FR1 through FR4) consensus sequence

<220> 
<221> VARIANT        
<222> (26)...(26)
<223> Xaa = Gly or Ser

<220> 
<221> VARIANT        
<222> (28)...(28)
<223> Xaa = Arg or Ser

<220> 
<221> VARIANT        
<222> (30)...(30)
<223> Xaa = Asn or Ser

<220> 
<221> VARIANT        
<222> (31)...(31)
<223> Xaa = His or Asn

<400> 41
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Xaa Gln Xaa Ile Xaa Xaa Asn
            20                  25                  30          
Leu His Trp Tyr Gln Gln Lys Pro Asp Glu Ser Pro Arg Leu Leu Ile
        35                  40                  45              
Asn Phe Ala Ser Arg Leu Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Tyr Trp Pro Leu
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 42
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse anti-proprotein convertase
      subtilisin/kexin type 9a (PSCK9) monoclonal antibody
      MAB1 epitope, PCSK9 catalytic domain residues 159-182

<400> 42
Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro
 1               5                  10                  15      
Asp Gly Gly Ser Leu Val Glu
            20              


<210> 43
<211> 692
<212> PRT
<213> Homo sapiens

<220> 
<223> human proprotein convertase subtilisin/kexin type 9a, (PSCK9)
      preproprotein, neural apoptosis regulated convertase 1 (NARC1,
      NARC-1), proprotein convertase 9 (PC9), subtilisin/kexin-like
      protease PC9, HCHOLA3, FH3, LDLCQ1

<400> 43
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu
 1               5                  10                  15      
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
            20                  25                  30          
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
        35                  40                  45              
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe
    50                  55                  60                  
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65                  70                  75                  80  
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg
                85                  90                  95      
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
            100                 105                 110         
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
        115                 120                 125             
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
    130                 135                 140                 
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145                 150                 155                 160 
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
                165                 170                 175     
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
            180                 185                 190         
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val
        195                 200                 205             
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
    210                 215                 220                 
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225                 230                 235                 240 
Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln
                245                 250                 255     
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
            260                 265                 270         
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
        275                 280                 285             
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu
    290                 295                 300                 
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305                 310                 315                 320 
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
                325                 330                 335     
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
            340                 345                 350         
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
        355                 360                 365             
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly
    370                 375                 380                 
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385                 390                 395                 400 
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
                405                 410                 415     
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
            420                 425                 430         
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
        435                 440                 445             
His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
    450                 455                 460                 
Ser Gly Pro Thr Arg Met Ala Thr Ala Val Ala Arg Cys Ala Pro Asp
465                 470                 475                 480 
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
                485                 490                 495     
Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His
            500                 505                 510         
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
        515                 520                 525             
Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala
    530                 535                 540                 
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr
545                 550                 555                 560 
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
                565                 570                 575     
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
            580                 585                 590         
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
        595                 600                 605             
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val
    610                 615                 620                 
Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly
625                 630                 635                 640 
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
                645                 650                 655     
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Gly Ala Val
            660                 665                 670         
Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser
        675                 680                 685             
Gln Glu Leu Gln
    690         


<210> 44
<211> 3636
<212> DNA
<213> Homo sapiens

<220> 
<223> human proprotein convertase subtilisin/kexin type 9a, (PSCK9)
      preproprotein, neural apoptosis regulated convertase 1 (NARC1,
      NARC-1), proprotein convertase 9 (PC9), subtilisin/kexin-like
      protease PC9, HCHOLA3, FH3, LDLCQ1 cDNA

<220> 
<221> CDS            
<222> (292)...(2370)
<223> PSCK9

<400> 44
cagcgacgtc gaggcgctca tggttgcagg cgggcgccgc cgttcagttc agggtctgag 60
cctggaggag tgagccaggc agtgagactg gctcgggcgg gccgggacgc gtcgttgcag 120
cagcggctcc cagctcccag ccaggattcc gcgcgcccct tcacgcgccc tgctcctgaa 180
cttcagctcc tgcacagtcc tccccaccgc aaggctcaag gcgccgccgg cgtggaccgc 240
gcacggcctc taggtctcct cgccaggaca gcaacctctc ccctggccct catgggcacc 300
gtcagctcca ggcggtcctg gtggccgctg ccactgctgc tgctgctgct gctgctcctg 360
ggtcccgcgg gcgcccgtgc gcaggaggac gaggacggcg actacgagga gctggtgcta 420
gccttgcgtt ccgaggagga cggcctggcc gaagcacccg agcacggaac cacagccacc 480
ttccaccgct gcgccaagga tccgtggagg ttgcctggca cctacgtggt ggtgctgaag 540
gaggagaccc acctctcgca gtcagagcgc actgcccgcc gcctgcaggc ccaggctgcc 600
cgccggggat acctcaccaa gatcctgcat gtcttccatg gccttcttcc tggcttcctg 660
gtgaagatga gtggcgacct gctggagctg gccttgaagt tgccccatgt cgactacatc 720
gaggaggact cctctgtctt tgcccagagc atcccgtgga acctggagcg gattacccct 780
ccacggtacc gggcggatga ataccagccc cccgacggag gcagcctggt ggaggtgtat 840
ctcctagaca ccagcataca gagtgaccac cgggaaatcg agggcagggt catggtcacc 900
gacttcgaga atgtgcccga ggaggacggg acccgcttcc acagacaggc cagcaagtgt 960
gacagtcatg gcacccacct ggcaggggtg gtcagcggcc gggatgccgg cgtggccaag 1020
ggtgccagca tgcgcagcct gcgcgtgctc aactgccaag ggaagggcac ggttagcggc 1080
accctcatag gcctggagtt tattcggaaa agccagctgg tccagcctgt ggggccactg 1140
gtggtgctgc tgcccctggc gggtgggtac agccgcgtcc tcaacgccgc ctgccagcgc 1200
ctggcgaggg ctggggtcgt gctggtcacc gctgccggca acttccggga cgatgcctgc 1260
ctctactccc cagcctcagc tcccgaggtc atcacagttg gggccaccaa tgcccaagac 1320
cagccggtga ccctggggac tttggggacc aactttggcc gctgtgtgga cctctttgcc 1380
ccaggggagg acatcattgg tgcctccagc gactgcagca cctgctttgt gtcacagagt 1440
gggacatcac aggctgctgc ccacgtggct ggcattgcag ccatgatgct gtctgccgag 1500
ccggagctca ccctggccga gttgaggcag agactgatcc acttctctgc caaagatgtc 1560
atcaatgagg cctggttccc tgaggaccag cgggtactga cccccaacct ggtggccgcc 1620
ctgcccccca gcacccatgg ggcaggttgg cagctgtttt gcaggactgt atggtcagca 1680
cactcggggc ctacacggat ggccacagcc gtcgcccgct gcgccccaga tgaggagctg 1740
ctgagctgct ccagtttctc caggagtggg aagcggcggg gcgagcgcat ggaggcccaa 1800
gggggcaagc tggtctgccg ggcccacaac gcttttgggg gtgagggtgt ctacgccatt 1860
gccaggtgct gcctgctacc ccaggccaac tgcagcgtcc acacagctcc accagctgag 1920
gccagcatgg ggacccgtgt ccactgccac caacagggcc acgtcctcac aggctgcagc 1980
tcccactggg aggtggagga ccttggcacc cacaagccgc ctgtgctgag gccacgaggt 2040
cagcccaacc agtgcgtggg ccacagggag gccagcatcc acgcttcctg ctgccatgcc 2100
ccaggtctgg aatgcaaagt caaggagcat ggaatcccgg cccctcagga gcaggtgacc 2160
gtggcctgcg aggagggctg gaccctgact ggctgcagtg ccctccctgg gacctcccac 2220
gtcctggggg cctacgccgt agacaacacg tgtgtagtca ggagccggga cgtcagcact 2280
acaggcagca ccagcgaagg ggccgtgaca gccgttgcca tctgctgccg gagccggcac 2340
ctggcgcagg cctcccagga gctccagtga cagccccatc ccaggatggg tgtctgggga 2400
gggtcaaggg ctggggctga gctttaaaat ggttccgact tgtccctctc tcagccctcc 2460
atggcctggc acgaggggat ggggatgctt ccgcctttcc ggggctgctg gcctggccct 2520
tgagtggggc agcctccttg cctggaactc actcactctg ggtgcctcct ccccaggtgg 2580
aggtgccagg aagctccctc cctcactgtg gggcatttca ccattcaaac aggtcgagct 2640
gtgctcgggt gctgccagct gctcccaatg tgccgatgtc cgtgggcaga atgactttta 2700
ttgagctctt gttccgtgcc aggcattcaa tcctcaggtc tccaccaagg aggcaggatt 2760
cttcccatgg ataggggagg gggcggtagg ggctgcaggg acaaacatcg ttggggggtg 2820
agtgtgaaag gtgctgatgg ccctcatctc cagctaactg tggagaagcc cctgggggct 2880
ccctgattaa tggaggctta gctttctgga tggcatctag ccagaggctg gagacaggtg 2940
cgcccctggt ggtcacaggc tgtgccttgg tttcctgagc cacctttact ctgctctatg 3000
ccaggctgtg ctagcaacac ccaaaggtgg cctgcgggga gccatcacct aggactgact 3060
cggcagtgtg cagtggtgca tgcactgtct cagccaaccc gctccactac ccggcagggt 3120
acacattcgc acccctactt cacagaggaa gaaacctgga accagagggg gcgtgcctgc 3180
caagctcaca cagcaggaac tgagccagaa acgcagattg ggctggctct gaagccaagc 3240
ctcttcttac ttcacccggc tgggctcctc atttttacgg gtaacagtga ggctgggaag 3300
gggaacacag accaggaagc tcggtgagtg atggcagaac gatgcctgca ggcatggaac 3360
tttttccgtt atcacccagg cctgattcac tggcctggcg gagatgcttc taaggcatgg 3420
tcgggggaga gggccaacaa ctgtccctcc ttgagcacca gccccaccca agcaagcaga 3480
catttatctt ttgggtctgt cctctctgtt gcctttttac agccaacttt tctagacctg 3540
ttttgctttt gtaacttgaa gatatttatt ctgggttttg tagcattttt attaatatgg 3600
tgacttttta aaataaaaac aaacaaacgt tgtcct                           3636

<210> 45
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic C-terminal His6 tag, 6-His tag

<400> 45
His His His His His His
 1               5      


<210> 46
<211> 357
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PCSK9)
      antibody MAB2 heavy chain optimized sequence

<400> 46
cagatcaccc tgaaagaatc cggccctgtg ctggtgaaac ccaccgagac actgaccctg 60
acctgcaccg tgtccggctt ctccctgtcc acctctggcg tgggcgtggg ctggatcaga 120
cagcctcccg gcaaggccct ggagtggctg gccgacattt ggtgggacga caacaagtac 180
tacaacccca gcctgaagtc ccggctgacc atctccaagg acacctccaa gaaccaggtg 240
gtgctgacca tgaccaatat ggaccccgtg gacaccgcca cctactactg cgcccggatc 300
accaccgagg gcggctttgc ttactggggc cagggcaccc tggtgacagt gtcctcc    357

<210> 47
<211> 321
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PCSK9)
      antibody MAB2 light chain optimized sequence

<400> 47
gacatccaga tgacccagtc cccctccagc ctgtccgcct ctgtgggcga cagagtgaca 60
atcacctgta gagccggcca gcggatctcc cacaacctgc actggtatca gcagaagccc 120
gacgagtccc ctcggctgct gatcaacttc gcctcccggc tgatctccgg cgtgccctcc 180
agattctccg gctctggctc cggcaccgac ttcaccctga caatctccag cctgcagccc 240
gaggacttcg ccacctacta ctgccagcag tccaactact ggcccctgac cttcggccag 300
ggcaccaagc tggaaatcaa g                                           321

<210> 48
<211> 357
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PCSK9)
      antibody MAB3 heavy chain optimized sequence

<400> 48
caggtgacac tgaaagagtc cggccccacc ctggtgaaac ccacccagac cctgaccctg 60
acttgcaccg tgtccggctt ctccctgtcc acctctggcg tgggcgtggg ctggatccgg 120
cagtctcctg gcaaggccct ggagtggctg gccgacattt ggtgggacga caacaagtac 180
tacaacccca gcctgaagtc ccggctgacc atctccaagg acacctccaa gaaccaggtg 240
gtgctgacca tgaccaatat ggaccccgtg gacaccgcca cctactactg cgcccggatc 300
accaccgagg gcggctttgc ttactggggc cagggcacac tggtgacagt gtcctcc    357

<210> 49
<211> 321
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic Humaneered monoclonal anti-proprotein
      convertase subtilisin/kexin type 9a (PCSK9)
      antibody MAB3 light chain optimized sequence

<400> 49
gacatccaga tgacccagtc cccctccagc ctgtccgcct ctgtgggcga cagagtgaca 60
atcacctgta gagccggcca gcggatctcc cacaacctgc actggtatca gcagaagccc 120
gacgagtccc ctcggctgct gatcaacttc gcctcccggc tgatctccgg cgtgccctcc 180
agattctccg gctctggctc cggcaccgac ttcaccctga caatctccag cctgcagccc 240
gaggacttcg ccacctacta ctgccagcag tccaactact ggcccctgac cttcggccag 300
ggcaccaagc tggaaatcaa g                                           321

<210> 50
<211> 17
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PCSK9) antibody MAB1 heavy chain
      variable region RT-PCR amplification primer V-H8

<400> 50
gtccctgcat atgtcyt                                                17

<210> 51
<211> 39
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PCSK9) antibody MAB1 heavy chain
      variable region RT-PCR amplification primer HCconstant

<400> 51
gcgtctagaa yctccacaca caggrrccag tggatagac                        39

<210> 52
<211> 19
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PCSK9) antibody MAB1 heavy chain
      variable region RT-PCR amplification primer Vkappa23

<400> 52
ctggaytyca gcctccaga                                              19

<210> 53
<211> 29
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse monoclonal anti-proprotein convertase
      subtilisin/kexin type 9a (PCSK9) antibody MAB1 heavy chain
      variable region RT-PCR amplification primer LCconstant

<400> 53
gcgtctagaa ctggatggtg ggaagatgg                                   29

<210> 54
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic C-terminal flexible linker and 6-His tag

<400> 54
Ala Ala Gly Ala Ser His His His His His His
 1               5                  10      


<210> 55
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic Avi tag for site-directed biotinylation

<400> 55
Gly Gly Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His
 1               5                  10                  15      
Glu
    

